Biogen Inc
BIIBHealthcare|Drug Manufacturers - General|USA
$172.34
-5.00 (-2.82%)
DCF (FCF)
$259.03
Tangible Book
$17.62
Graham Number
$77.87
Earnings Power
$149.79
Upcoming Data Readouts (31)
Jun 2026
Est. completion
P1Lupus Nephritis
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
NCT06064929n=14
Jul 2026
Est. completion
P3Muscular Atrophy, Spinal
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
NCT04729907n=115
Aug 2026
Est. completion
P1Healthy Volunteer
A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old
NCT07133828n=78
Sep 2026
Est. completion
P3Lupus Erythematosus, Systemic
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567n=562
Sep 2026
Est. completion
P3Lupus Erythematosus, Systemic
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04895241n=548
Dec 2026
Est. completion
P3Antibody-mediated Rejection
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
NCT06685757n=120
Feb 2027
Est. completion
Muscular Atrophy, Spinal
Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)
NCT04317794n=74
Mar 2027
Est. completion
Postpartum Depression
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
NCT07398469n=200
Apr 2027
Est. completion
May 2027
Est. completion
P3Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
NCT03958877n=152
May 2027
Est. completion
P3Immunoglobulin A Nephropathy (IgAN)
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357n=454
Jun 2027
Est. completion
P3Spinal Muscular Atrophy
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
NCT05067790n=45
Jun 2027
Est. completion
P1Muscular Atrophy, Spinal
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
NCT06555419n=58
Jun 2027
Est. completion
Aug 2027
Est. completion
P3Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
NCT04856982n=158
Sep 2027
Est. completion
Oct 2027
Est. completion
P2Multiple Sclerosis
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
NCT05418010n=40
Nov 2027
Est. completion
P3Friedreich Ataxia
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)
NCT06953583n=255
Feb 2028
Est. completion
P2Microvascular Inflammation
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
NCT07219043n=81
Jun 2028
Est. completion
Awaiting Results (3)
Trials past primary completion date but still active — data readout may be imminent.
Mar 2026
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
NCT06053749Mar 2026
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05925049Feb 2026
P2
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
NCT05348785